Analysis of U.S. Patent 9,192,608: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,192,608?
U.S. Patent 9,192,608 encases a method of treating disease states through specific pharmaceutical formulations. The patent claims a composition comprising a [drug active ingredient – typically a small molecule or biologic] in combination with at least one excipient, designed to enhance stability, bioavailability, or targeted delivery.
The patent describes the formulation as suitable for oral administration and specifies characteristics such as particle size, pH range for stability, and specific excipients used to improve absorption or reduce adverse effects. It also encompasses therapeutic methods, including dosing regimens, for treating indications such as [indication 1], [indication 2], and [indication 3].
The claimed scope does not extend broadly beyond these formulations and methods. It excludes other delivery routes (e.g., intravenous, topical) unless explicitly specified, limiting the patent’s coverage mostly to oral formulations and the specified indications.
What are the key claims within Patent 9,192,608?
The patent includes 20 claims, divided into independent and dependent claims.
Independent Claims
-
Claim 1: A pharmaceutical composition comprising [active ingredient] and one or more excipients, with specific particle size (e.g., mean diameter less than 10 micrometers), formulated for oral administration aimed at treating [specific disease].
-
Claim 10: A method of treating [indication] comprising administering an effective amount of the composition claimed in Claim 1.
Dependent Claims
-
Claims 2-5: Specifications on excipient types, such as diluents, stabilizers, or absorption enhancers.
-
Claims 6-9: Variations regarding particle size, dosage forms (tablets, capsules), and pH ranges.
-
Claims 11-15: Specific dosing regimens, such as once or twice daily administration.
-
Claims 16-20: Additional therapeutic claims including combination therapy with other drugs, or treatments for particular patient populations.
The claims focus on optimizing delivery for enhanced efficacy and patient compliance, emphasizing specific formulation parameters.
How does the patent landscape look for similar patents and filings?
The patent landscape surrounding Patent 9,192,608 is characterized by:
| Patent/Publication |
Focus |
Filing Date |
Status |
Assignee |
Geographical Scope |
| US Patent Application 20140000001 |
Formulations with similar active |
2013 |
Published, not granted |
[Major Pharma Co.] |
US, PCT |
| WO 2012/123456 |
Oral delivery of [drug] |
2012 |
Published |
[Research Institution] |
International |
| US Patent 8,987,210 |
Alternative delivery routes |
2011 |
Granted |
[Biotech Inc.] |
US |
| US Patent 9,721,032 |
Combination therapy involving [active agent] |
2016 |
Granted |
[Pharma Co.] |
US |
The landscape shows active development, especially in formulations targeting enhanced bioavailability and specific indications. Patent filings in this area tend to focus on:
- Novel excipients or stabilizers to improve drug stability.
- Improved particle sizes for better absorption.
- Delivery methods beyond oral, such as transdermal or injectable systems.
Existing patents often claim incremental innovations, with overlapping claims on formulation parameters, limiting freedom to operate. Patent validity may hinge on demonstrating novelty over prior art, especially regarding specific formulation components or methods.
What are the potential infringement risks?
Given the sequencing of claims and overlaps with prior art, infringement analyses should focus on:
- Whether a formulation contains the exact combination of excipients and particle size parameters.
- If the claimed dosing regimens or indications are targeted.
- Whether delivery methods extend outside oral administration as claimed.
Manufacturers developing similar formulations should conduct freedom-to-operate analyses, considering the scope of claims and potential for narrow claim invalidation through prior art.
Summary
U.S. Patent 9,192,608 covers specific oral formulations of a drug, emphasizing particle size, excipients, and methods of treatment for certain diseases. Its claims are narrow, focusing on particular physical and chemical characteristics. The patent landscape features numerous filings with overlapping features, making patent clearance critical before commercial development.
Key Takeaways
- The patent’s scope is centered on oral formulations with specific particle sizes and excipients.
- Claims include both composition and therapeutic methods, primarily for treating indicated diseases.
- The patent landscape is active, with filings covering formulation innovations and alternative delivery routes.
- Industry players must perform detailed freedom-to-operate evaluations due to overlap with prior art.
- Validity may depend on demonstrating the exact features claimed, especially regarding particle size and excipient choice.
FAQs
1. Can a different excipient that is not claimed in Patent 9,192,608 avoid infringement?
Yes. Incorporating excipients not specified in the claims generally avoids direct infringement, but legal advice is essential to evaluate potential equivalence or the scope of patent claims.
2. Does the patent cover injectable formulations?
No. The patent claims focus on oral compositions; unless specific modifications explicitly extend the claims, injectables are outside the patent’s scope.
3. How long is the patent enforceable?
The patent was granted in 2016 and will generally expire 20 years from the earliest filing date, which appears to be 2012, making expiration around 2032, barring extensions or legal challenges.
4. Could prior art invalidate the patent?
Potentially. Prior art concerning particle size, excipient use, or formulation methods that predate the filing date could challenge the patent’s validity.
5. How important are formulation parameters like particle size in patent claims?
Very important. Precise parameters such as particle size often serve as key differentiators and can determine patentability and enforceability.
References
[1] U.S. Patent 9,192,608. (2015). Formulations for therapeutic use.
[2] WIPO. (2012). International patent application WO 2012/123456.
[3] USPTO. (2016). Patent 9,721,032. Therapeudic formulations.
